PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Aberrations and clinical significance of BRAF in malignant melanoma: A series of 60 cases in Chinese Uyghur.

Abstract Malignant melanoma (MM) is a highly malignant melanocytic tumor, it occurs mostly in the skin, the mucous membrane close to the skin, but also in the tunicae rhagoides and the pia mater. The Uyghur is the largest ethnic group living in the Xinjiang Uyghur Autonomous Region of China, accounting for 46% of the total population of 20 million. Large-scale studies on MMs in Asian countries are limited. This study aimed to investigate BRAF mRNA expression and mutations in Chinese Uyghur patients with MMs and to identify the clinical features associated with these parameters.Formalin-fixed, paraffin wax-embedded tumor sections from 60 MMs were analyzed for BRAF expression using reverse transcription polymerase chain reaction (RT-PCR). Exons 11 and 15 of BRAF were analyzed for the presence of mutations using PCR and DNA sequencing. Sixty MMs were followed by mobile phone for survival analysis.BRAF mRNA expression was higher in MMs than in pigmented moles and normal skin tissues. Fourteen of 60 MMs had BRAF mutations. The frequency of BRAF mutations was significantly higher in patients younger than 60 years (10/28, 4/32, P = .02). A significant difference was observed in the frequency of BRAF mutations among specimens of mucosal, acral, chronic sun-induced damage (CSD), and non-CSD MMs (2/10, 3/19, 8/25, 1/6, P = .002). No significant association was found among BRAF mutations, sex, ulceration, or lymph node metastasis. MMs lymph node metastasis (hazard ratio 2.54 [95% confidence interval 1.062 - 6.066], P = .01) affected survival.This study indicated that BRAF mutations and expression might serve as independent adverse prognostic factors in melanoma.
PMID
Related Publications

BRAF and NRAS mutations in melanoma and melanocytic nevi.

Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.

Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.

Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort.

Analysis of KIT mutations and c-KIT expression in Chinese Uyghur and Han patients with melanoma.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 29505523
OWN - NLM
STAT- MEDLINE
DCOM- 20180309
LR  - 20180309
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 1
DP  - 2018 Jan
TI  - Aberrations and clinical significance of BRAF in malignant melanoma: A series of 
      60 cases in Chinese Uyghur.
PG  - e9509
LID - 10.1097/MD.0000000000009509 [doi]
AB  - Malignant melanoma (MM) is a highly malignant melanocytic tumor, it occurs mostly
      in the skin, the mucous membrane close to the skin, but also in the tunicae
      rhagoides and the pia mater. The Uyghur is the largest ethnic group living in the
      Xinjiang Uyghur Autonomous Region of China, accounting for 46% of the total
      population of 20 million. Large-scale studies on MMs in Asian countries are
      limited. This study aimed to investigate BRAF mRNA expression and mutations in
      Chinese Uyghur patients with MMs and to identify the clinical features associated
      with these parameters.Formalin-fixed, paraffin wax-embedded tumor sections from
      60 MMs were analyzed for BRAF expression using reverse transcription polymerase
      chain reaction (RT-PCR). Exons 11 and 15 of BRAF were analyzed for the presence
      of mutations using PCR and DNA sequencing. Sixty MMs were followed by mobile
      phone for survival analysis.BRAF mRNA expression was higher in MMs than in
      pigmented moles and normal skin tissues. Fourteen of 60 MMs had BRAF mutations.
      The frequency of BRAF mutations was significantly higher in patients younger than
      60 years (10/28, 4/32, P = .02). A significant difference was observed in the
      frequency of BRAF mutations among specimens of mucosal, acral, chronic
      sun-induced damage (CSD), and non-CSD MMs (2/10, 3/19, 8/25, 1/6, P = .002). No
      significant association was found among BRAF mutations, sex, ulceration, or lymph
      node metastasis. MMs lymph node metastasis (hazard ratio 2.54 [95% confidence
      interval 1.062 - 6.066], P = .01) affected survival.This study indicated that
      BRAF mutations and expression might serve as independent adverse prognostic
      factors in melanoma.
CI  - Copyright (c) 2017 The Authors. Published by Wolters Kluwer Health, Inc. All
      rights reserved.
FAU - Kang, Xiaojing
AU  - Kang X
AD  - Department of Dermatology.
FAU - Zeng, Ying
AU  - Zeng Y
AD  - Department of Dermatology.
FAU - Liang, Junqin
AU  - Liang J
AD  - Department of Dermatology.
FAU - Li, Jing
AU  - Li J
AD  - Department of Dermatology.
FAU - Ren, Danyang
AU  - Ren D
AD  - Department of Dermatology.
FAU - Chai, Li
AU  - Chai L
AD  - Department of Dermatology.
FAU - Sun, Zhenzhu
AU  - Sun Z
AD  - Department of Pathology, People's Hospital of Xinjiang Uyghur Autonomous Region, 
      Urumqi, Xinjiang, China.
FAU - Yu, Shirong
AU  - Yu S
AD  - Department of Dermatology.
FAU - Wu, Xiujuan
AU  - Wu X
AD  - Department of Dermatology.
FAU - Han, Wen
AU  - Han W
AD  - Department of Pathology, People's Hospital of Xinjiang Uyghur Autonomous Region, 
      Urumqi, Xinjiang, China.
FAU - Wang, Weijia
AU  - Wang W
AD  - Department of Dermatology.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - EC 2.7.11.1 (BRAF protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
SB  - AIM
SB  - IM
MH  - Aged
MH  - Asian Continental Ancestry Group/genetics
MH  - China/epidemiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Melanoma/*genetics/metabolism/mortality
MH  - Middle Aged
MH  - Mutation
MH  - Proto-Oncogene Proteins B-raf/*genetics/metabolism
MH  - Skin Neoplasms/*genetics/metabolism/mortality
MH  - Survival Analysis
EDAT- 2018/03/06 06:00
MHDA- 2018/03/10 06:00
CRDT- 2018/03/06 06:00
PHST- 2018/03/06 06:00 [entrez]
PHST- 2018/03/06 06:00 [pubmed]
PHST- 2018/03/10 06:00 [medline]
AID - 10.1097/MD.0000000000009509 [doi]
AID - 00005792-201801050-00020 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Jan;97(1):e9509. doi: 10.1097/MD.0000000000009509.